

DEVELOPMENT STAGE INVESTMENT OPPORTUNITY



Imessa Research LLC

Imessa Research manufactures next generation instruments to purify and measure size of particles used in drug and vaccine delivery

Website: www.imessaresearch.com

Headquarters: Salt Lake City, Utah


Type: Nanotechnology, Pharma

Investment

Series: Pre-seed

Min Investment: \$1M

Use of funds



Key Metrics

- 100% self-funded
- Prototype is built and working
- Software is ready
- Three companies in pilot studies
- Seeking funding for further software development, commercialization and marketing

Team



Shoeleh Assemi
Founder and CEO
More than 25 years experience in nanotechnology, and nanoparticle analysis

Science Team:

Onur Tasci | Stephen Williams

Business advisor:

Kapil Sharma

Contact

Shoeleh Assemi

3852425656

sassemi@imessaresearch.com

www.imessaresearch.com

Overview

Imessa Research is the manufacturer of a next generation instrument, to be used in the production and quality control of drug delivery nanoparticles. Imessa Research firmly believes that future medicine will rely on nanoparticles and invites you to join forces to enter this exciting market at its early development stage. The working prototype is ready. Funds will be used to integrate the current software and commercialize the working prototype to enter the market in the next 9-12 months.

Highlights

Therapy of the 21st century

Particles as small as 1/1000 thickness of human hair, called nanoparticles, are now used to deliver vaccines and drugs directly to the target organ. Size, load, and purity of the nanoparticle drug carriers are critical parameters to be determined.

Current Technology

Current technologies to purify and measure size of nanoparticles can be time consuming, inaccurate or need expert users, imparting a high cost to nanoparticle-based drug manufacturers, and patients

Let's provide a solution

How would the healthcare industry benefit from fast, accurate and turn-key analysis of drug delivery vehicles at production, quality control and post-production stages. Imessa Research addresses all the above with its technology.

The progress

A working prototype has been built and tested with a variety of nanoparticles. Software for data acquisition and data processing are written. Funds are needed to integrate the software, add sensors and automation, and product commercialization.


Traction

The product is already in pilot studies with three Utah-based companies for the analysis of nanoparticles in drug delivery systems, producing accurate and reproducible results in a very short time and pending CRO contract with at least one company.

The Market

Nanoparticle analysis


The nanoparticle analysis market is booming, with demands from sectors like nanomedicine, material science, cosmetics, and fabrics. Imessa Research plans to expand sales to universities and research institutes, as well as foreign markets in Europe, Asia, and Middle East in 2027.



The Competition

| Feature | Malvern DLS | Waters Wyatt AF4 | Postnova AF4 | Imessa Nanosize |
|-------------------------------|-------------|--------------------|--------------|-----------------|
| Turn key | ✓ | | | ✓ |
| 24/7 operation | | ✓ | ✓ | ✓ |
| AI/Machine learning | | | | ✓ |
| Separation capability | | ✓ | ✓ | ✓ |
| No extra accessory for sizing | ✓ | | | ✓ |
| Lease option | | | | ✓ |
| Competitive Price | ✓ | | | ✓ |

Financial projections



See the full pitch presentation at WeROC 2023

4:00 pm, Tuesday September 5, 2023

Ivory Ballroom, Thomas Monson Center, 411 E S Temple St, Salt Lake City